You are here: Industry Insights > mRNA Vaccines

News List

Touchlight and GSK Sign License Agreement for Use of Enzymatic dbDNA Production Technology for mRNA Manufacturing Biotech Newswire
July 24, 2024
Touchlight announced a license agreement with GSK, a global leader in biopharmaceutical innovation.
Breakthroughs in Melanoma Immunotherapy & RNA Vaccines Daivd Orchard Webb/PharmaSources
July 03, 2023
Melanoma is a type of skin cancer that develops from pigment-producing cells called melanocytes.
First study to show waning effectiveness of 3rd dose of mRNA vaccines WorldPharmaNews
February 14, 2022
A nationwide study from the U.S. Centers for Disease Control and Prevention (CDC) is the first to show that immunity against severe COVID-19 disease begins to wane 4 months after receipt of the third dose of an mRNA vaccine (Pfizer or Moderna).
Johnson & Johnson's Covid-19 vaccine holds up in US durability study FirstWordPharma
January 07, 2022
Findings were unveiled Thursday from the largest US study to date on the durability of COVID-19 vaccines, with Johnson & Johnson's jab producing a robust result in terms...
Tonix and Kansas State University to develop mRNA vaccines for Covid-19 Pharmaceutical-Technology
January 06, 2022
The ZNP technology could offer increased stability to mRNA vaccines at various temperatures.
Delaying second dose of mRNA COVID-19 vaccine produces stronger immune response WorldPharmaNews
December 02, 2021
The first peer-reviewed study in North America examining the timing between the first and second doses of COVID-19 mRNA vaccines shows that a longer dose interval leads to a stronger immune response. The study is funded by the Government of Canada...
Biotage expands production capacity to ease lipid bottlenecks cphi-online
August 19, 2021
New site in Cardiff boosts the company's production capacity for equipment crucial in the supply chain for mRNA vaccines production
Investigation of reports of myocarditis in connection with COVID-19 mRNA vaccines firstwordpharma
June 07, 2021
Very rare reports received worldwide of myocarditis with a possible link to the use of mRNA vaccines against COVID-19 are currently under investigation.
Precision NanoSystems joins Danaher's Life Sciences Platform firstwordpharma
June 02, 2021
Precision NanoSystems (PNI) has been acquired by Danaher Corporation's Life Sciences platform. PNI is a global leader in technologies and solutions for the development of genetic medicines, including mRNA vaccines and therapeutics.
Merck KGaA boosts lipid capacity to meet vaccine demand cphi-online
May 31, 2021
The company's new synthetic cholesterol product will help meet the demand for mRNA vaccines, including Pfizer-BioNTech Covid-19 Vaccine

Previous page 1 2 Next page